ストックスクリーナーアプリを入手
68.50
2.59%
1.73
プレマーケット:
68.61
0.11
+0.16%
Apogee Therapeutics Inc (APGE) 最新ニュース
This Xponential Fitness Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday - Benzinga
This Rocket Lab Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
This Union Pacific Analyst Turns Bullish; Here Are Top 3 Upgrades For Wednesday - Benzinga
This Evommune Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Truist Securities initiates coverage of Apogee Therapeutics (APGE) with hold recommendation - MSN
Apogee Therapeutics Inc. (NASDAQ:APGE) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Truist initiates Apogee Therapeutics stock with Hold on high bar - Investing.com
Analysts Offer Insights on Healthcare Companies: Apogee Therapeutics (APGE), Wave Life Sciences (WVE) and Telix Pharmaceuticals (OtherTLPPF) - The Globe and Mail
Aug Spikes: Is Apogee Therapeutics Inc backed by strong institutional buyingQuarterly Risk Review & Short-Term High Return Strategies - baoquankhu1.vn
BTIG Research Reiterates "Buy" Rating for Apogee Therapeutics (NASDAQ:APGE) - MarketBeat
HighVista Strategies LLC Grows Position in Apogee Therapeutics Inc. $APGE - MarketBeat
APGEApogee Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction - AOL.com
Boxer Capital Management LLC Acquires New Holdings in Apogee Therapeutics Inc. $APGE - MarketBeat
Braidwell LP Sells 39,767 Shares of Apogee Therapeutics Inc. $APGE - MarketBeat
CEO Michael Henderson Sells 20,000 Shares of Apogee Therapeutics Inc (APGE) - GuruFocus
Apogee Therapeutics (NASDAQ:APGE) CEO Michael Thomas Henderson Sells 20,000 Shares - MarketBeat
Apogee Therapeutics CEO Sells 20,000 Shares - TradingView
Apogee Therapeutics (APGE) CEO sells 20,000 shares in pre-set 10b5-1 plan - Stock Titan
The Technical Signals Behind (APGE) That Institutions Follow - Stock Traders Daily
Barclays PLC Buys 33,494 Shares of Apogee Therapeutics Inc. $APGE - MarketBeat
A Look At Apogee Therapeutics (APGE) Valuation After Wider Losses And A New Shelf Registration - Sahm
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million - AOL.com
Wedbush Raises Price Target on Apogee Therapeutics (APGE) - Finviz
10 Most Shorted Biotech Stocks to Buy According to Hedge Funds - Insider Monkey
Jefferies Financial Group Inc. Sells 74,273 Shares of Apogee Therapeutics Inc. $APGE - MarketBeat
RBC Capital Initiates Coverage of Apogee Therapeutics (APGE) with Outperform Recommendation - MSN
Performance Recap: What is Apogee Therapeutics Incs 5 year growth outlookJuly 2025 Pullbacks & Accurate Buy Signal Alerts - baoquankhu1.vn
Apogee Therapeutics (NASDAQ:APGE) Insider Carl Dambkowski Sells 5,500 Shares - MarketBeat
Apogee Therapeutics (APGE) CMO sells shares under 10b5-1 trading plan - Stock Titan
T. Rowe Price (APGE) holds 6.21M shares, 11.3% stake disclosed - Stock Titan
Vanguard Group Inc. Has $89.22 Million Stock Holdings in Apogee Therapeutics Inc. $APGE - MarketBeat
Rafferty Asset Management LLC Acquires 23,585 Shares of Apogee Therapeutics Inc. $APGE - MarketBeat
Apogee Therapeutics (APGE) Gets a Buy from Mizuho Securities - The Globe and Mail
Citi Remains a Buy on Apogee Therapeutics (APGE) - The Globe and Mail
CFO at Apogee Therapeutics (APGE) sells 2,000 shares in planned trades - Stock Titan
Apogee Therapeutics Teases 52-Week Zumi Durability Data, Phase III Path at TD Cowen Conference - MarketBeat
Is Rising R&D Spend And New Equity Shelf Altering The Investment Case For Apogee Therapeutics (APGE)? - Yahoo Finance
APGE: RBC Capital Lowers Price Target to $82, Maintains Sector P - GuruFocus
Apogee Therapeutics (APGE) Stock Analysis: Exploring a 47.76% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Apogee Therapeutics (NASDAQ:APGE) Price Target Raised to $95.00 - MarketBeat
RBC Lowers Price Target on Apogee Therapeutics to $82 From $83, Keeps Sector Perform, Speculative Risk - marketscreener.com
Apogee’s Deeper Losses and New Shelf Filing Test Its High-Risk Pipeline Strategy (APGE) - Sahm
Apogee Therapeutics Stock: Clinical-Stage Risks, Unproven Pipeline, and Uncertain Path to Profitability - TipRanks
Decoding Apogee Therapeutics Inc (APGE): A Strategic SWOT Insigh - GuruFocus
RBC Capital lowers Apogee Therapeutics stock price target on dosing outlook By Investing.com - Investing.com Australia
RBC Capital lowers Apogee Therapeutics stock price target on dosing outlook - Investing.com Australia
Key facts: Apogee Therapeutics posts $285.6M loss; plans Phase 3 trial - TradingView
APGE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Apogee Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Apogee Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Wedbush Adjusts Price Target on Apogee Therapeutics to $95 From $90, Maintains Outperform Rating - marketscreener.com
APOGEE THERAPEUTICS ($APGE) Releases Q4 2025 Earnings - Quiver Quantitative
Apogee Therapeutics (NASDAQ:APGE) Releases Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
APGE: Strong pipeline progress and robust cash reserves position for key data and trial milestones in 2026 - TradingView
Apogee Therapeutics 2025 10-K: $0 Revenue; EPS $(4.22) - TradingView
Apogee Therapeutics (NASDAQ: APGE) advances long-acting AD biologics - Stock Titan
Apogee Therapeutics (NASDAQ: APGE) details 2025 loss and strong cash runway - Stock Titan
Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results - GlobeNewswire
Precision Trading with Apogee Therapeutics Inc. (APGE) Risk Zones - Stock Traders Daily
What Investors Should Know About a $1.5 Million Apogee Insider Sale Amid a 60% Stock Rally - AOL.com
1.20%
0.06%
大文字化:
|
ボリューム (24 時間):